title: Chronic Hepatitis C and Alcohol Abuse: The Single Center Experience of Novi Sad - Serbia.
abstract: Chronic ethyl alcohol consuming is well known independent negative predictor of unfavorable natural course and therapy outcome of Chronic Hepatitis C (CHC) infection.
  
  
  
  The aim of the present study was to clarify the impact of alcohol consumption on fibrosis rate progression in patients with CHC and Sustained Virologic Response (SVR) rates in patients undergoing treatment with pegylated interferon and ribavirin.
  
  
  
  This cross sectional retrospective study included 807 CHC patients underwent liver biopsy and hospitalized at Clinical center of Vojvodina, Novi Sad, Serbia. According to the alcohol consumption equal or greater than 50 g/day prior to liver biopsy, patients were divided into two groups. We compared demographic, clinical, virologic and histopathological markers of CHC, as well as response to antiviral therapy.
  
  
  
  We find statistically significant difference (p=0.001) in gender, but not in age (p=0.081), estimated duration of the CHC (p=0.470) and hepatitis C genotype (p=0.545) between two groups. Among patients with CHC who consume alcohol ≥50 g/day there were significantly higher incidence of intravenous drug users (p=0.000). Binary logistic regression showed that the only independent predictors of moderate to severe fibrosis (fibrosis ≥2) were age (p=0.000) and alcohol use (p=0.027). There was not statistically significant difference in SVR rate between two groups (p=0.810).
  
  
  
  We believe that this good result in treatment outcome was the consequence of proper selection of patients based primarily on regulations of Republic of Serbia on the necessity of abstinence from the use of alcohol and psychoactive substances at least one year before starting antiviral therapy.
authors.forename: Tomislav
authors.initials: T
authors.lastname: Preveden
authors.forename: Maja
authors.initials: M
authors.lastname: Ruzic
authors.affiliation: Clinical Centre of Vojvodina, Clinic for Infectious Diseases, Medical Faculty University of Novi Sad, Serbia.
authors.forename: Dajana
authors.initials: D
authors.lastname: Lendak
authors.forename: Maria
authors.initials: M
authors.lastname: Pete
authors.forename: Ludovico
authors.initials: L
authors.lastname: Abenavoli
authors.forename: Snezana
authors.initials: S
authors.lastname: Brkic
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000150:complications* / Q000473:pathology; D000998:Antiviral Agents / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D055771:Serbia; D000072230:Sustained Virologic Response
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons